- Peptide therapeutics contract API manufacturing involves the outsourcing of active pharmaceutical ingredient (API) production for peptide-based drugs. This approach allows pharmaceutical companies to leverage specialized expertise and facilities, ensuring efficient and cost-effective manufacturing processes
- The market's growth is significantly driven by the increasing adoption of peptide-based therapeutics, advancements in synthesis technology, and the trend toward outsourcing pharmaceutical manufacturing to specialized API manufacturers. Peptides are gaining traction in pharmaceutical research due to their high specificity, low toxicity, and favorable therapeutic index
- North America is expected to dominate the peptide therapeutics contract API manufacturing market with share of 40.3%, driven by a strong pharmaceutical industry advanced healthcare infrastructure, and significant investments in biotechnology
- Asia-Pacific is expected to be the fastest growing region in the peptide therapeutics contract API manufacturing market with a share of 23.6%, driven by rapid healthcare infrastructure development, increasing demand for innovative therapies, and supportive government policies
- Chemical synthesis segment is expected to dominate the market with a market share of 41.8%, due to the high efficiency and scalability of SPPS. This method enables automated, stepwise peptide production with high purity and supports large-scale manufacturing, further contributing to its widespread adoption in therapeutic peptide production
Frequently Asked Questions
The market is segmented based on Global Peptide Therapeutics Contract API Manufacturing Market Segmentation, By Scale of Operation (Pre-Clinical and Clinical), Synthesis Method (Non- Chemical Synthesis and Chemical Synthesis), Enterprise Type (Large Enterprise and Small and Medium Enterprise) - Industry Trends and Forecast to 2032
.
The Global Peptide Therapeutics Contract Api Manufacturing Market size was valued at USD 3.48 USD Billion in 2024.
The Global Peptide Therapeutics Contract Api Manufacturing Market is projected to grow at a CAGR of 9% during the forecast period of 2025 to 2032.
The major players operating in the market include Bachem Group (Switzerland), CordenPharma (Germany), Lonza (Switzerland), PolyPeptide Group (Sweden) and AmbioPharm Inc. (U.S.).
The market report covers data from the North America.
